 This study found that adding a Latinab to standard chemotherapy regimens improved progression-free survival in patients with EGFR, mutated non-small cell lung cancer, NSCLC, but also increased the risk of side effects such as fatigue, anorexia, weight loss, and renal toxicity. This article was authored by Roelof GP Gittenbeek, Vincent van der Neut, Joachim G. J. Vieritz, and others.